Abstract: A kinetic structural component may have a flexible structure having at least one degree of freedom. The flexible structure can be moved between a compressed position and an expanded position or vice versa. The flexible structure may have at least one substructure which is configured, when said flexible structure is in the expanded position, to expand to form a curve or an arc and/or linearly.

Abstract: A structural component may have a carrier structure and a substructure arranged on the carrier structure and having a variable contour. The substructure may have an adjustment mechanism with a plurality of adjustment elements. The adjustment mechanism may be configured to adjust the adjustment elements between a compressed position and an expanded position in order to vary the contour.

Abstract: A structural component may have a flexible structure with at least one adjusting mechanism, which may be formed at least from a plurality of folded elements or lever elements and spacing elements that are coupled to one another in such a way that their upper surfaces are connected to one another by an upper flat element and their lower surfaces are connected to one another by a lower flat element. The upper flat element and the lower flat element may be configured to be moved in a defined manner in the event of a tilting movement of the flexible structure.

Abstract: A unit (10) for causing angular momentum (11) about an axis (13a), which unit includes, inflow sequence, an incoming fluid pathway (12), a first fluid pathway (14a) in fluid communication with the incoming fluid pathway (12), a second fluid pathway (16a) in fluid communication with the incoming fluid pathway (12), an outgoing fluid pathway (18) in fluid communication with the first and second fluid pathway (14a, 16a), a flow regulating means (20a) for regulating the proportional flow in the first and second fluid pathways (14a, 16a), and wherein the first and second fluid pathways (14a, 16a) are respectively arranged about the axis (13a) generally in a plane transverse to the axis (13a).

Abstract: The present invention relates to a systemic formulation, in particular an oral formulation, for the prophylaxis and/or treatment of coeliac disease, i.e. for use in the prophylaxis and/or treatment of coeliac disease.

Abstract: The present invention relates to a formulation in particular an oral formulation for the prophylaxis and treatment of TG2-related disorders like fibrosis in particular diabetic nephropathy and/or diabetic associated non-alcoholic steatohepatitis (NASH) and/or non-alcoholic steatohepatitis, and its use in the prophylaxis and/or treatment of fibrosis in particular nephropathy, NASH, idiopathic pulmonary fibrosis, and cystic fibrosis. Further, the present application relates also to the use of (S,E)-methyl-7-(1-(2-(2-ethylbutylamino)-2-oxoethyl)-2-oxo-1,2-dihydro-pyridin-3-ylamino)-6-(1-methyl-1H- imidazole-5-carboxamido)-7-oxohept-2-enoate as hepatoprotectant, i.e. as hepatoprotective agent.

Abstract: A structural component may have a carrier structure and a substructure arranged on the carrier structure and having a variable contour. The substructure may have an adjustment mechanism with a plurality of adjustment elements. The adjustment mechanism may be configured to adjust the adjustment elements between a compressed position and an expanded position in order to vary the contour.

Abstract: Disclosed is an optimized pharmaceutical formulation for the treatment of inflammatory conditions of the esophagus. A pharmaceutical formulation in the form of an orodispersible effervescent tablet is stable, easy to produce, and can be used without dissolving same in a liquid. It is not necessary to drink anything with the tablet as this would reduce the time that the budesonide solution remains in the affected regions of the esophagus. The effervescent tablet of the invention surprisingly resulted in an unexpectedly high rate of histological remission in patients with active eosinophilic esophagitis.

Abstract: A structural component may have a flexible structure with at least one adjusting mechanism, which may be formed at least from a plurality of folded elements or lever elements and spacing elements that are coupled to one another in such a way that their upper surfaces are connected to one another by an upper flat element and their lower surfaces are connected to one another by a lower flat element.

Abstract: A kinetic structural component may have a flexible structure having at least one degree of freedom. The flexible structure can be moved between a compressed position and an expanded position or vice versa. The flexible structure may have at least one substructure which is configured, when said flexible structure is in the expanded position, to expand to form a curve or an arc and/or linearly.

Abstract: An optimized pharmaceutical formulation for the treatment of inflammatory diseases of the colon is disclosed, wherein the pharmaceutical formulation is a capsule containing pellets, which capsule is suitable for oral administration and delivers the active substance in a targeted manner to the site of action, namely the colon. This is achieved by a complex and multiple coating of pellets, which permit a modified release of active substance. The release of the active substance is at its maximum only in the colon, with at the same time low blood plasma levels. The results of the pharmaceutical tests concerning in vitro release are corroborated by the results in pharmaco-kinetic and clinical studies and the clinical efficacy demonstrated by these. The formulation according to the invention has a very good medicinal safety.

Abstract: An optimized pharmaceutical formulation for the treatment of inflammatory diseases of the colon is disclosed, wherein the pharmaceutical formulation is a capsule containing pellets, which capsule is suitable for oral administration and delivers the active substance in a targeted manner to the site of action, namely the colon. This is achieved by a complex and multiple coating of pellets, which permit a modified release of active substance. The release of the active substance is at its maximum only in the colon, with at the same time low blood plasma levels. The results of the pharmaceutical tests concerning in vitro release are corroborated by the results in pharmaco-kinetic and clinical studies and the clinical efficacy demonstrated by these. The formulation according to the invention has a very good medicinal safety.

Abstract: Disclosed is an optimized pharmaceutical formulation for the treatment of inflammatory conditions of the esophagus. A pharmaceutical formulation in the form of an orodispersible effervescent tablet is stable, easy to produce, and can be used without dissolving same in a liquid. It is not necessary to drink anything with the tablet as this would reduce the time that the budesonide solution remains in the affected regions of the esophagus. The effervescent tablet of the invention surprisingly resulted in an unexpectedly high rate of histological remission in patients with active eosinophilic esophagitis.

Abstract: A head restraint for a seat back of a vehicle seat may have two lateral wings. A topmost surface of the wings may flare from top to bottom in a driving position.

Abstract: Disclosed is an optimized pharmaceutical formulation for the treatment of inflammatory conditions of the esophagus. A pharmaceutical formulation in the form of an orodispersible effervescent tablet is stable, easy to produce, and can be used without dissolving same in a liquid. It is not necessary to drink anything with the tablet as this would reduce the time that the budesonide solution remains in the affected regions of the esophagus. The effervescent tablet of the invention surprisingly resulted in an unexpectedly high rate of histological remission in patients with active eosinophilic esophagitis.

Abstract: Disclosed is an optimized pharmaceutical formulation for the treatment of inflammatory conditions of the esophagus. A pharmaceutical formulation in the form of an orodispersible effervescent tablet is stable, easy to produce, and can be used without dissolving same in a liquid. It is not necessary to drink anything with the tablet as this would reduce the time that the budesonide solution remains in the affected regions of the esophagus. The effervescent tablet of the invention surprisingly resulted in an unexpectedly high rate of histological remission in patients with active eosinophilic esophagitis.

Abstract: Disclosed is an optimized pharmaceutical formulation for the treatment of inflammatory conditions of the esophagus. A pharmaceutical formulation in the form of an orodispersible effervescent tablet is stable, easy to produce, and can be used without dissolving same in a liquid. It is not necessary to drink anything with the tablet as this would reduce the time that the budesonide solution remains in the affected regions of the esophagus. The effervescent tablet of the invention surprisingly resulted in an unexpectedly high rate of histological remission in patients with active eosinophilic esophagitis.

Abstract: Disclosed is an optimized pharmaceutical formulation for the treatment of inflammatory conditions of the esophagus. A pharmaceutical formulation in the form of an orodispersible effervescent tablet is stable, easy to produce, and can be used without dissolving same in a liquid. It is not necessary to drink anything with the tablet as this would reduce the time that the budesonide solution remains in the affected regions of the esophagus. The effervescent tablet of the invention surprisingly resulted in an unexpectedly high rate of histological remission in patients with active eosinophilic esophagitis.

Abstract: The present invention relates to a pure polymorph of Nor-UDCA or Bis-nor-UDCA, or of a pharmaceutically acceptable salt thereof. The invention further provides a pharmaceutical composition comprising the polymorph of the invention, and a method for preparing the polymorph. The invention includes the pharmaceutical use of the polymorph or of the pharmaceutical composition of the invention.